The biggest drawback of a current diabetes therapy is the treatment of the consequences not
the cause of the disease. Regardless of the diabetes type, preservation and recovery of …

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells
located in the endocrine pancreas in areas known as islets of Langerhans. The current …

There is increasing evidence showing that chronic inflammation is an important pathogenic
mediator of the development of type 2 diabetes (T2D). It is now generally accepted that …

Recovery of functional β‐cell mass continues to be an ongoing challenge in treating
diabetes. Initial work studying β‐cells suggested apoptotic β‐cell death as a main contributor …

The pathogenesis of hyperglycemia observed in most forms of diabetes is intimately tied to
the islet β cell. Impairments in propeptide processing and secretory function, along with the …

Type 1 diabetes, has been recognized as an autoimmune disease. Like other
immunological conditions, regulation of immune response is a key strategy to control the …

摘要背景研究显示, 联合使用中草药津力达颗粒能够显著提高二甲双胍的降糖水平,
然而应用津力达颗粒治疗的优势人群尚未明确. 本研究旨在采用分层分析方法 …

Peptide hormones are first produced as larger precursor prohormones that require
endoproteolytic cleavage to liberate the mature hormones. A structurally conserved but …

Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse
hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes …

The Nod-like receptor 3 (NLRP3) inflammasome is an intracellular sensor that sets off the
innate immune system in response to microbial-derived and endogenous metabolic danger …